NeonMind Announces Launch of Functional Mushroom Coffees as Dietary Supplements in the US
NeonMind Announces Launch of
Functional Mushroom Coffees as
Dietary Supplements in the US
VANCOUVER, BC / ACCESSWIRE / June 29, 2021 / NeonMind Biosciences
Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) ("NeonMind'' or the "Company"), a
psychedelic drug development company, is pleased to announce that it is launched its
NeonMind branded functional mushroom coffee products as dietary supplements in the
United States. The initial launch includes two ground coffee SKUs that are now available
for delivery anywhere within the US. Two instant coffee SKUs are anticipated to be
added within a month.
The new website for US sales is live at intl.neonmind.com and is supported by Shopify.
Products can be purchased individually and can be ordered as a subscription to receive
a 10% discount The website was built to be mobile friendly and focus on a customer-
first strategy. Consumers can sign up to NeonMind's newsletter to receive the latest
news, product releases and recipe information.
Each of the functional mushroom blends and botanicals selected in NeonMind coffees
include adaptogens, which means that they work with one's body to help manage
physical, mental and emotional stressors. Functional mushroom specifically refers to
mushroom varieties that have a health benefit beyond providing nutrition. Functional
mushrooms found in NeonMind coffees, such as cordyceps, lion's mane, reishi, and
turkey tail; offer long-term physical, neurological and immunological benefits.
The initial product launch will feature two varieties of ground coffee. The Protect Blend
is a Peruvian Medium Roast French Vanilla Coffee, Turkey Tail, Cordyceps, Moringa
extract, and Amla extract. These ingredients have the proven benefit of stress relief,
immune support, and cognitive support. The Focus Blend is a Peruvian Dark Roast
Coffee with Lion's Mane extract, Reishi extract, Gotu Kola extract, and Brahmi extract.
These ingredients are a healthy source of fungal polysaccharides with immuno-
modulating properties that help improve memory and cognitive function, increase
alertness, support the immune system and fight mental and physical stress. The
Company will soon launch its two instant coffee blends in the US as dietary
supplements.
The NeonMind coffee dietary supplements follow all FDA regulations that focus on
Comprehensive GMP (Good Manufacturing Practices) to ensure the identity, purity,
quality, strength and composition of dietary supplements. NeonMind only uses certified
organic mushroom extracts which go through the decoction process (traditional water
boiling) to maximize the bioavailability of the product. NeonMindfollows strict US
pharmacopeia guidelines for lead and other chemicals required by Proposition 65 for
safe and daily intake. All final production batches are sent to a third party lab for
stringent microbial testing in order for the copacker to release the product certificate of
analysis which signifies that the product is safe for the consumer market.
The global functional mushroom market was valued at USD $25.4 billion in 2020, and it
is estimated to register a compound annual growth rate of 8.44% during the forecast
period 2021-2026, according to a report by Mordor Intelligence.
About NeonMind Biosciences Inc.
NeonMind is engaged in preclinical research to develop potential clinical treatments and
wellness products to address obesity and weight management conditions and to
promote health and wellness. The Company operates three divisions: (i) a
pharmaceutical division engaged in drug development of psychedelic compounds with
two lead psilocybin-based drug candidates targeting obesity; (ii) a medical services
division focused on launching specialty mental health clinics that integrate psychedelic
therapeutics into traditional psychotherapy settings; and (iii) a consumer products
division that currently sells mushroom-infused products to promote health and wellness.
In its pharmaceutical division, NeonMind has two distinct psilocybin drug development
programs targeting obesity. NeonMind's first drug candidate employs psilocybin as an
agonist to the serotonin receptor 5- HT2A, which is involved in the hallucinogenic effect
of psychedelics. The Company's second drug candidate employs low-dose psilocybin as
an agonist to the 5-HT2C receptor, which controls appetite.
NeonMind established a medical services division with the goal of launching NeonMind-
branded specialty mental health clinics in Canada that incorporate evidence-backed
innovative treatments to address a variety of mental health needs.
NeonMind's consumer division currently sells NeonMind branded coffee products in
Canada through NeonMind's direct to consumer e-commerce platform in Canada and
the US.
For more information on NeonMind, go towww.NeonMindBiosciences.com.
Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.
Tel: 416-750-3101
Investor Relations:
Edge Communications
Tel: 1-866-318-6874
KCSA Strategic Communications
Scott Eckstein/Tim Regan
Tel: 212-896-1210
Media Inquiries:
KCSA Strategic Communications
Annie Graf
Tel: 786-390-2644
The Canadian Securities Exchange has not reviewed, approved nor disapproved the
contents of this news release.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this press release constitute forward-looking
information. These statements relate to future events or NeonMind's future
performance. The use of any of the words "could", "expect", "believe", "will",
"projected","estimated" and similar expressions and statements relating to matters that
are not historical facts are intended to identify forward-looking information and are
based on NeonMind's current belief or assumptions as to the outcome and timing of
such future events. Actual future results may differ materially. In particular, NeonMind's
drug development plans, its ability to retain key personnel, and its expectation as to the
development of its intellectual property and other steps in its preclinical and clinical
drug development constitute forward-looking information. Actual results and
developments may differ materially from those contemplated by forward-looking
information. Readers are cautioned not to place undue reliance on forward-looking
information. The statements made in this press release are made as of the date hereof.
NeonMind disclaims any intention or obligation to publicly update or revise any forward-
looking information, whether as a result of new information, future events or otherwise,
except as may be expressly required by applicable securities laws.
SOURCE: NeonMind Biosciences Inc.